ex vivo drug sensitivity testing and multi-omics profiling

Conditions: Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Large Cell Lymphoma; Refractory Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Hodgkin Lymphoma; Refractory Childhood Malignant Germ Cell Neoplasm; Recurrent Childhood Brain Tumor; Recurrent Childhood Brainstem Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Ependymoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Gliosarcoma; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Neoplasm; Refractory Childhood Malignant Neoplasm

Summary: functional precision medicine (fpm) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (dst) and genomic profiling to determine the optimal individualized therapy for cancer patients. in this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for dst and genomic profiling from the south florida area, which is 69% hispanic and 18% black. tumor cells collected from tissue taken during routine biopsy or surgery will be tested.

primary objective: the primary objective of the study is to determine feasibility of providing pediatric cancer patients with access to personalized treatment options and clinical management recommendations based on functional precision medicine (fpm), the combination of ex vivo drug sensitivity testing (dst) and genomic profiling. secondary objective: the secondary objective of the study is to compare individual outcomes (response and disease-free survival) in patients with pediatric cancers treated with fpm-guided therapy as compared to non-fpm guided (conventional) therapy. exploratory objective: to explore associations between tumor molecular characteristics (genomic and transcriptomic variation) and ex vivo drug response with respect to patient ethnicity.

Eligibility criteria:
inclusion criteria: * patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity. subjects with suspected or confirmed diagnosis of recurrent or refractory cancer subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing subjects or their parents or legal guardians willing to sign informed consent subjects aged 7 to 17 willing to sign assent exclusion criteria: * subjects who do not have malignant tissue available and accessible the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. patients with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.

Keywords: ex vivo drug sensitivity assay genomic profiling functional precision medicine biomarker development